PacBio Q2 Revenue Misses, New CEO and Restructuring Announced; CFO Adopts 10b5-1 Plan
PACB is trading near its 52-week low of $1.09 (6.4% above the low) on elevated volume (2.2× avg).
Summary
PacBio reported Q2 revenue of $39.0M, missing estimates, and announced a new CEO and a restructuring to cut $30M-$40M in annual costs. CFO Jim Gibson also adopted a 10b5-1 plan to sell up to 661,685 shares.
Key Events · Earnings and Guidance · PACB
-
Q2 Revenue Miss
Revenue of $39.0M fell short of the $40.07M consensus, and adjusted loss per share of $0.14 was a penny worse than expected.
-
CEO Change
Mark Van Oene appointed CEO effective August 5, 2026, replacing Christian Henry, who remains on the board.
-
Restructuring Announced
Plan to cut ~40 employees (~8% of workforce) and reduce annual operating expenses by $30M-$40M by end of 2027; $2.0M in charges expected in Q3 2026.
-
CFO 10b5-1 Trading Plan
CFO Jim R. Gibson adopted a Rule 10b5-1 plan on May 22, 2026, for potential sale of up to 661,685 shares from August 21, 2026 through March 15, 2027.
Analysis · PACB · Industrial Applications And Services
PacBio's Q2 revenue of $39.0M missed the $40.07M consensus, and the adjusted loss of $0.14 per share was a penny worse than expected. The company simultaneously announced a CEO transition — COO Mark Van Oene replaces Christian Henry — and a restructuring that will cut about 8% of the workforce to save $30M-$40M annually by the end of 2027. Separately, CFO Jim Gibson adopted a 10b5-1 trading plan covering up to 661,685 shares starting August 21. The combination of a top-line miss, leadership change, cost-cutting, and a CFO selling plan creates significant uncertainty for a company already trading near $1.16 with a negative equity position.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PACB was trading at $1.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $361.9M. The 52-week trading range was $1.09 to $2.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.